TY - JOUR
T1 - Global Healthcare Study on Psoriasis (GHSP)
T2 - cohort profile and first findings
AU - Maul, Julia Tatjana
AU - Fröhlich, Fabienne
AU - Nielsen, Mia Louise
AU - Maul, Lara Valeska
AU - Torres, Tiago
AU - Thyssen, Jacob
AU - Armstrong, April
AU - Oon, Hazel H.
AU - Ji, Mei
AU - Kang, Xiaojing
AU - Valenzuela, Fernando
AU - Romiti, Richardo
AU - Carvalho, André V.E.de
AU - Novoa, Farah
AU - Sousa, Marco
AU - Luz, Martim
AU - Guevara, Bryan Edgar K.
AU - doss, Nejib
AU - Gisondi, Paulo
AU - Chularojanamontri, Leena
AU - Kündig, Thomas M.
AU - Egeberg, Alexander
AU - Thomsen, Simon Francis
AU - Didaskalu, Johannes A.
N1 - Publisher Copyright:
© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/.
PY - 2026/5
Y1 - 2026/5
N2 - Purpose: Despite the intention of international psoriasis treatment guidelines to cover all patients globally, disparities persist in the availability and accessibility of adequate therapy in many countries. The Global Healthcare Study on Psoriasis (GHSP) aims to study patient characteristics, disease impact, treatment accessibility and healthcare systems worldwide. This study provides a description and data analysis of 22 countries. Participants: The GHSP cohort was initiated in 2020, and the number of recruiting centres has gradually grown. Participants are recruited by dermatologists at reference centres worldwide. Data are collected using a standardised assessment questionnaire comprising 88 items, administered by trained experts. Findings to date: By 26 October 2024, cross-sectional data had been collected from 3950 psoriasis patients at 130 reference centres in 22 countries on six continents. The majority (55.7%) of patients were male, and the median (IQR) body mass index was 26.5 (23.7–30.1) kg/m2. The median (IQR) Psoriasis Area and Severity Index was 5.0 (2.0–11.4), and median (IQR) Dermatology Life Quality Index was 7.0 (2.0–14.0). Psoriatic arthritis was present in 20.2% of the patients and nail psoriasis in 36.7%. Additionally, 16.5% of patients were current smokers, and 26.4% reported regular alcohol consumption. Future plans: By identifying inequalities, special patient populations and country-specific differences, the GHSP will guide the development of strategies to enhance psoriasis care on a global level. Future directions include expanding the study to additional countries and sites worldwide, while transitioning into a long-term global registry of skin diseases, including atopic dermatitis and hidradenitis suppurativa, termed ‘Global Healthcare Registry on Skin Diseases’.
AB - Purpose: Despite the intention of international psoriasis treatment guidelines to cover all patients globally, disparities persist in the availability and accessibility of adequate therapy in many countries. The Global Healthcare Study on Psoriasis (GHSP) aims to study patient characteristics, disease impact, treatment accessibility and healthcare systems worldwide. This study provides a description and data analysis of 22 countries. Participants: The GHSP cohort was initiated in 2020, and the number of recruiting centres has gradually grown. Participants are recruited by dermatologists at reference centres worldwide. Data are collected using a standardised assessment questionnaire comprising 88 items, administered by trained experts. Findings to date: By 26 October 2024, cross-sectional data had been collected from 3950 psoriasis patients at 130 reference centres in 22 countries on six continents. The majority (55.7%) of patients were male, and the median (IQR) body mass index was 26.5 (23.7–30.1) kg/m2. The median (IQR) Psoriasis Area and Severity Index was 5.0 (2.0–11.4), and median (IQR) Dermatology Life Quality Index was 7.0 (2.0–14.0). Psoriatic arthritis was present in 20.2% of the patients and nail psoriasis in 36.7%. Additionally, 16.5% of patients were current smokers, and 26.4% reported regular alcohol consumption. Future plans: By identifying inequalities, special patient populations and country-specific differences, the GHSP will guide the development of strategies to enhance psoriasis care on a global level. Future directions include expanding the study to additional countries and sites worldwide, while transitioning into a long-term global registry of skin diseases, including atopic dermatitis and hidradenitis suppurativa, termed ‘Global Healthcare Registry on Skin Diseases’.
KW - Adult dermatology
KW - Dermatological epidemiology
KW - Psoriasis
UR - https://www.scopus.com/pages/publications/105039464002
U2 - 10.1136/bmjopen-2025-112891
DO - 10.1136/bmjopen-2025-112891
M3 - Article
C2 - 42156142
AN - SCOPUS:105039464002
SN - 2044-6055
VL - 16
JO - BMJ open
JF - BMJ open
IS - 5
M1 - e112891
ER -